Zepbound, which received approval for treating obesity from the Food and Drug Administration in early November, notched nearly $176 million in its first quarter on the market.
Meet TikTok’s ‘GLP-1 influencers,’ documenting their weight loss journeys on Ozempic, Wegovy and Mounjaro
Pfizer’s twice-daily GLP-1 danuglipron reached its primary endpoint in a Phase 2b trial but caused high rates of side effects like nausea and vomiting.
‘It’s not about more weight loss.’ Have obesity drugmakers maxed out?